A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
NIH Begins Clinical Trial Evaluating Second COVID-19 Booster Shots in Adults
Latest News
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV